Welcome, Guest |
TOPIC:
U.S. Food and Drug Administration Approves Voxilaprevir 6 years 9 months ago #25004
U.S. Food and Drug Administration Approves Gilead’s Vosevi™ (Sofosbuvir/Velpatasvir/Voxilaprevir) for Re-Treatment of Adults with Chronic Hepatitis C Virus www.gilead.com/news/press-releases/2017/...ic-hepatitis-c-virus YMMV | |
U.S. Food and Drug Administration Approves Voxilaprevir 6 years 9 months ago #25013
"Yee Haw"!!!!!! This email address is being protected from spambots. You need JavaScript enabled to view it. Genotype 3 VL 4,100,000 ALT 101 AST 71 Treatment Naive Started Sof/Dac Jan 12, 2016 VL= <15 4 weeks in. AST/ALT normal. VL=UNDETECTED 8 weeks in. SVR4= Virus back. 3,300,000 Started generic Epclusa Sep. 23, 2017 4 weeks in <15 *Detected. 12 weeks in <15 *Not Detected. 16 weeks in <15 *Not Detected. Finished 24 weeks treatment 3-17-18 SVR5 <15 Not Detected. SVR 20 <15 Not Detected. SVR 44 <15 Not Detected. Thank you Jesus. Thank you Dr. James The following user(s) said Thank You: klhilde | |
Time to create page: 0.069 seconds